peptide wiki

Mechanism

Pre-mixed three-peptide blend combining GHK-Cu, KPV, and MOTS-c. GHK-Cu is the copper-binding tripeptide glycyl-L-histidyl-L-lysine, studied for collagen synthesis, wound healing, and antioxidant signaling. KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH and acts as an anti-inflammatory via NF-kB inhibition without melanocortin-receptor activation. MOTS-c is a 16-residue mitochondrial-derived peptide that activates AMPK and is studied for metabolic and exercise-mimetic effects. None of the three is FDA-approved as an injectable therapeutic, and there is no controlled human efficacy or safety data for this specific combination — the rationale is inferred from the individual research compounds.

Studied uses

• recovery, anti-inflammatory, and tissue-repair support (research only)
• skin and collagen support (research only)
• metabolic and mitochondrial support (research only)

Identification

Typical dose	Vendor-dependent; GHK-Cu ~1-2 mg, KPV 200-500 mcg, MOTS-c 5-10 mg per dose in research contexts. No validated combination dosing exists.
Half-life	Each component has a short, poorly characterized systemic half-life in humans; no combination pharmacokinetic data.

Safety

Not FDA-approved; sold as a research-only / grey-market blend. No combination-specific human safety data. Excess parenteral copper exposure is a theoretical concern. Not evaluated by WADA as a blend.